P571: ORAL AZACITIDINE VS MIDOSTAURIN AS MAINTENANCE TREATMENT FOR FLT3 MUTANT ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: AN INDIRECT TREATMENT COMPARISON

• E. N. Oliva,
• C. Chen,
• S. N. Rahim,
• B. Seuro,
• A. Vasconcelos,
• L. Gaugler,
• B. Skikne,
• T. Prebet,
• H. Cameron,
• C. Beach,
• G. Thompson

Affiliations

E. N. Oliva

1 Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy

C. Chen

2 Bristol Myers Squibb, Princeton, NJ

S. N. Rahim

2 Bristol Myers Squibb, Princeton, NJ

B. Seuro

3 Eversana, San Diego, CA, United States of America

A. Vasconcelos

2 Bristol Myers Squibb, Princeton, NJ

L. Gaugler

2 Bristol Myers Squibb, Princeton, NJ

B. Skikne

2 Bristol Myers Squibb, Princeton, NJ

T. Prebet

2 Bristol Myers Squibb, Princeton, NJ

H. Cameron

3 Eversana, San Diego, CA, United States of America

C. Beach

2 Bristol Myers Squibb, Princeton, NJ

G. Thompson

2 Bristol Myers Squibb, Princeton, NJ